Boehringer Ingelheim GmbH – Product Pipeline Review

Global Markets Direct’s, ‘Boehringer Ingelheim GmbH – Product Pipeline Review – 2016’, provides an overview of the Boehringer Ingelheim GmbH’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Boehringer Ingelheim GmbH, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Boehringer Ingelheim GmbH

The report provides overview of Boehringer Ingelheim GmbH including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Boehringer Ingelheim GmbH’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Boehringer Ingelheim GmbH’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Boehringer Ingelheim GmbH’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Boehringer Ingelheim GmbH

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Boehringer Ingelheim GmbH’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Boehringer Ingelheim GmbH Snapshot 6

Boehringer Ingelheim GmbH Overview 6

Key Information 6

Key Facts 6

Boehringer Ingelheim GmbH - Research and Development Overview 7

Key Therapeutic Areas 7

Boehringer Ingelheim GmbH - Pipeline Review 14

Pipeline Products by Stage of Development 14

Pipeline Products - Monotherapy 15

Pipeline Products - Combination Treatment Modalities 16

Pipeline Products - Partnered Products 17

Pipeline Products - Out-Licensed Products 19

Boehringer Ingelheim GmbH - Pipeline Products Glance 21

Boehringer Ingelheim GmbH - Late Stage Pipeline Products 21

Boehringer Ingelheim GmbH - Clinical Stage Pipeline Products 23

Boehringer Ingelheim GmbH - Early Stage Pipeline Products 26

Boehringer Ingelheim GmbH - Drug Profiles 29

(empagliflozin + linagliptin) 29

(linagliptin + metformin hydrochloride ER) 30

(olodaterol hydrochloride + tiotropium bromide) 31

idarucizumab 34

(empagliflozin + metformin hydrochloride XR) 35

adalimumab biosimilar 36

afatinib dimaleate 37

bevacizumab biosimilar 42

empagliflozin 43

nintedanib 45

risankizumab 50

rituximab biosimilar 52

volasertib trihydrochloride 53

BI-1026706 56

BI-1361849 57

BI-144807 58

BI-409306 59

FX-125L 61

HM-61713 63

BI-836826 64

BI-836845 65

BI-836858 67

BI-1005273 68

BI-1060469 69

BI-113608 70

BI-416970 71

BI-425809 72

BI-443651 73

BI-655064 74

BI-655088 75

BI-655130 76

BI-685509 77

BI-836880 78

BI-836909 79

BI-853520 80

BI-860585 81

BI-894999 82

PXS-4728A 83

Small Molecule for Oncology 84

AR-116082 85

BI-113823 86

BI-1467335 87

BI-186908 88

BI-207524 Follow-Up 89

BI-703704 90

BI-882370 91

CNX-012 92

CNX-012570 93

linagliptin 94

Monoclonal Antibody for Ophthalmology 95

olcegepant 96

Small Molecule 2 for Oncology 98

Small Molecule 2 to Agonize Glucocorticoid Receptor for Rheumatoid Arthritis 99

Small Molecule 3 for Oncology 100

Small Molecule for Respiratory Diseases 101

Small Molecule to Agonize Glucocorticoid Receptor for Inflammation 102

Small Molecule to Agonize Glucocorticoid Receptor for Rheumatoid Arthritis 103

Small Molecule to Inhibit PI4KIII beta for Rhinovirus Infection 104

Small Molecules for Respiratory Disorders 105

Small Molecules to Inhibit HIV-1 Reverse Transcriptase for HIV-1 Infection 106

Small Molecules to Inhibit TRPC4/C5 for Depression, Anxiety and Nephropathy 107

Synthetic Peptide for CardioMetabolic Disease 108

Antibody for Oncology 109

BI-665915 110

Small Molecule for HIV 111

Small Molecule for HIV-1 Infection 112

Small Molecule to Agonize Glucocorticoid Receptor 113

Small Molecule to Agonize ROR-Gamma for Autoimmune and Allergic Disorders 114

Small Molecules for Oncology 115

Small Molecules for Schizophrenia 116

Small Molecules for Undisclosed Indication 117

Small Molecules to Inhibit K-Ras for Oncology 118

Small Molecules to Inhibit Kinases for Oncology 119

Synthetic Peptide to Agonize Glucagon and GLP-1 for Metabolic Disorders 120

Boehringer Ingelheim GmbH - Pipeline Analysis 121

Boehringer Ingelheim GmbH - Pipeline Products by Target 121

Boehringer Ingelheim GmbH - Pipeline Products by Route of Administration 125

Boehringer Ingelheim GmbH - Pipeline Products by Molecule Type 126

Boehringer Ingelheim GmbH - Pipeline Products by Mechanism of Action 127

Boehringer Ingelheim GmbH - Recent Pipeline Updates 130

Boehringer Ingelheim GmbH - Dormant Projects 166

Boehringer Ingelheim GmbH - Discontinued Pipeline Products 169

Discontinued Pipeline Product Profiles 169

Boehringer Ingelheim GmbH - Company Statement 172

Boehringer Ingelheim GmbH - Locations And Subsidiaries 174

Head Office 174

Other Locations & Subsidiaries 174

Appendix 179

Methodology 179

Coverage 179

Secondary Research 179

Primary Research 179

Expert Panel Validation 179

Contact Us 179

Disclaimer 180

List of Tables

List of Tables

Boehringer Ingelheim GmbH, Key Information 12

Boehringer Ingelheim GmbH, Key Facts 12

Boehringer Ingelheim GmbH – Pipeline by Indication, 2016 14

Boehringer Ingelheim GmbH – Pipeline by Stage of Development, 2016 20

Boehringer Ingelheim GmbH – Monotherapy Products in Pipeline, 2016 21

Boehringer Ingelheim GmbH – Combination Treatment Modalities in Pipeline, 2016 22

Boehringer Ingelheim GmbH – Partnered Products in Pipeline, 2016 23

Boehringer Ingelheim GmbH – Partnered Products/ Combination Treatment Modalities, 2016 24

Boehringer Ingelheim GmbH – Out-Licensed Products in Pipeline, 2016 25

Boehringer Ingelheim GmbH – Out-Licensed Products/ Combination Treatment Modalities, 2016 26

Boehringer Ingelheim GmbH – Pre-Registration, 2016 27

Boehringer Ingelheim GmbH – Phase III, 2016 28

Boehringer Ingelheim GmbH – Phase II, 2016 29

Boehringer Ingelheim GmbH – Phase I, 2016 30

Boehringer Ingelheim GmbH – Preclinical, 2016 32

Boehringer Ingelheim GmbH – Discovery, 2016 34

Boehringer Ingelheim GmbH – Pipeline by Target, 2016 127

Boehringer Ingelheim GmbH – Pipeline by Route of Administration, 2016 131

Boehringer Ingelheim GmbH – Pipeline by Molecule Type, 2016 132

Boehringer Ingelheim GmbH – Pipeline Products by Mechanism of Action, 2016 133

Boehringer Ingelheim GmbH – Recent Pipeline Updates, 2016 136

Boehringer Ingelheim GmbH – Dormant Developmental Projects,2016 172

Boehringer Ingelheim GmbH – Discontinued Pipeline Products, 2016 175

Boehringer Ingelheim GmbH, Subsidiaries 180

List of Figures

List of Figures

Boehringer Ingelheim GmbH – Pipeline by Top 10 Indication, 2016 14

Boehringer Ingelheim GmbH – Pipeline by Stage of Development, 2016 20

Boehringer Ingelheim GmbH – Monotherapy Products in Pipeline, 2016 21

Boehringer Ingelheim GmbH – Combination Treatment Modalities in Pipeline, 2016 22

Boehringer Ingelheim GmbH – Partnered Products in Pipeline, 2016 23

Boehringer Ingelheim GmbH – Out-Licensed Products in Pipeline, 2016 25

Boehringer Ingelheim GmbH – Pipeline by Top 10 Target, 2016 127

Boehringer Ingelheim GmbH – Pipeline by Route of Administration, 2016 131

Boehringer Ingelheim GmbH – Pipeline by Molecule Type, 2016 132

Boehringer Ingelheim GmbH – Pipeline Products by Top 10 Mechanism of Action, 2016 133

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports